CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2− Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis

SIMPLE SUMMARY: Recently updated results of clinical studies have confirmed that cyclin-dependent kinase 4/6 (CDK4/6) inhibitors such as palbociclib (Palbo), ribociclib (Ribo), and abemaciclib (Abem) plus letrozole/anastrozole (NSAI) significantly prolong survival compared to placebo plus NSAI in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Ni, Han, Jiaqi, Liu, Zijian, He, Jinlan, Tian, Kun, Chen, Nianyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340287/
https://www.ncbi.nlm.nih.gov/pubmed/37444496
http://dx.doi.org/10.3390/cancers15133386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340287/
https://www.ncbi.nlm.nih.gov/pubmed/37444496
http://dx.doi.org/10.3390/cancers15133386

Ejemplares similares